Revolution Medicines Insider Sold Shares Worth $3,153,807, According to a Recent SEC Filing
MT newswire2026/09/15 07:39Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma
GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.
Alphabet's Waymo, Local Partners Plan 2027 Tokyo Autonomous Taxi Launch
Germany's DAX 40 fell to 25,200 points, down 0.8% in 24 hours
Borr Drilling Divests Mexican Oil Drilling Joint Ventures
Crypto prices
More
